E
LKFT

Ergoteles’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Ergoteles’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,972
Closed -$445K – 1702
2022
Q2 		$445K Buy
7,972
+2,001
+34% +$119K 0.01% 892
2022
Q1 		$370K Buy
+5,971
New +$365K 0.01% 777
2021
Q3 		– Sell
-12,268
Closed -$845K – 1389
2021
Q2 		$845K Sell
12,268
-20,386
-62% -$1.55M 0.02% 563
2021
Q1 		$2.52M Buy
+32,654
New +$3.01M 0.08% 249

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Ergoteles's LKFT Position: Q3 2022 in Review

Ergoteles sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2022, closing a stake of 7,972 shares — an estimated $445K sold.

Ergoteles first reported a position in LKFT in Q1 2021 and held it in 4 quarters. The position peaked at $2.52M in Q1 2021. 84 funds tracked by Wall St. Rank hold LKFT as of Q3 2022.

  • Ergoteles reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 7,972 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2022, an estimated $445K.
  • Ergoteles first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2021 and held it in 4 quarters.
  • Ergoteles's Lakefront Biotherapeutics American Depositary Shares position peaked at $2.52M in Q1 2021.
  • 84 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.